U.S. Chamber Presses HHS on Evidence-Based Vaccine Review

The U.S. Chamber of Commerce is pressing Health and Human Services Secretary Robert F. Kennedy, Jr. to ground the department's implementation of a new childhood vaccine executive order in "evidence-based science" while preserving existing vaccine access and coverage.

In a letter dated September 2, 2026, addressed to Kennedy at HHS headquarters in Washington, D.C., the Chamber invoked the Executive Order on childhood vaccines that President Trump signed on August 10, 2026. The business lobby described the administration's next steps as decisive for stakeholder confidence across the healthcare economy.

"The business community shares the Administration's goal of ensuring Americans have access to safe, effective, and innovative healthcare," the Chamber wrote. "Regarding the President's most recent Executive Order on childhood vaccines, signed August 10, 2026, it is critical that HHS's next steps are firmly grounded in evidence-based science and maintain existing vaccine access and coverage."

The letter frames those two objectives — scientific rigor and continuity of access — as prerequisites for what the Chamber calls credibility, clarity, and predictability. The groups it says depend on that predictability span the healthcare value chain: families, employers, physicians and other healthcare providers, insurers, and manufacturers.

That breadth of stakeholders is the core of the Chamber's argument. Vaccine policy is not, in the lobby's telling, a narrow public-health question. It is a commercial one, with direct consequences for the companies that make, distribute, and administer vaccines and the employers that rely on a functioning healthcare system.

"The U.S. Chamber has long supported policies that encourage medical innovation while preserving appropriate protections for patients and manufacturers," the letter states. "The business community has a direct and substantial stake in federal vaccine policy. Our members create, manufacture, administer, and provide access to vaccines."

The Chamber positions itself as a longstanding ally of medical innovation, not an opponent of regulatory oversight. Its formulation — encouraging innovation while preserving "appropriate protections for patients and manufacturers" — signals the lobby's preference for a review process that scrutinizes without destabilizing.

The timing matters. The August 10 executive order has put childhood vaccine policy back at the center of the federal health agenda, and HHS under Kennedy now holds the implementation pen. The Chamber's letter, arriving less than a month after the order was signed, amounts to an early effort by the country's largest business lobby to shape the rulemaking and review framework before it hardens.

For manufacturers and insurers, the stakes are concrete. Any change to how childhood vaccines are reviewed, recommended, or covered would ripple through product pipelines, liability exposure, and insurance benefit design. The Chamber's demand for predictability reflects those commercial realities.

The letter does not specify what HHS should do beyond grounding its steps in evidence-based science and maintaining access and coverage. Its function is to set boundaries: the business community will accept a review process, but it expects that process to be scientifically anchored and non-disruptive to the existing immunization infrastructure.

Kennedy's department now faces the task the Chamber has defined: implementing the August 10 order in a way that satisfies both the administration's appetite for scrutiny of childhood vaccines and the business community's demand for evidence-based, access-preserving policy. How HHS structures that scientific review will determine whether the predictability the Chamber is seeking materializes — or erodes.